[DOI] [PubMed] [Google Scholar] 25.Konosic S., Petricevic M., Ivancan V., Konosic L., Goluza E., Krtalic B., Drmic D., Stupnisek M., Seiwerth S., Sikiric P
doi: 10.1038/sj.onc.1210796 18 BartoliniD.StabileA
Combining incretin-based medicines could compound gastrointestinal effects, dehydration risk, and hypoglycemia risk when other glucose-lowering drugs are involved
Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA
10.1038/nri2653 Nat
"Fewer than 1 in 10 people who could benefit from a GLP-1 are taking one." "People living with obesity need treatment options that meet them where they are and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," she said in the same press release